The liver is a common non-exocrine target in primary Sjögrens syndrome: A retrospective reviewReportar como inadecuado

The liver is a common non-exocrine target in primary Sjögrens syndrome: A retrospective review - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Gastroenterology

, 2:21

First Online: 13 September 2002Received: 16 April 2002Accepted: 13 September 2002


BackgroundThe autoimmune destruction of exocrine glands that defines primary Sjögren-s syndrome 1°SS often extends to non-exocrine organs including the liver. We aimed to determine the prevalence of liver disease in patients with 1°SS and to evaluate the association of this complication with other non-exocrine features and serologic markers of autoimmunity and systemic inflammation.

MethodsWe reviewed 115 charts of patients with 1°SS and further analyzed the 73 cases that fulfilled the European Epidemiology Center Criteria, seeking evidence for clinical and subclinical liver disease.

ResultsLiver function tests had been determined in 59 of the 73 patients. Of those, 29 patients 49.1% had abnormal liver function tests including 20.3% with clinically overt hepatic disease. Liver disease was the most common non-exocrine feature in this cohort. Risk factors for abnormal liver function tests were distributed similarly between the patients with and without liver disease. In 60% of patients with abnormal liver function tests no explanation for this complication was found except for 1°SS. Liver involvement was significantly more common in 1°SS patients who also had evidence of lung, kidney and hematological abnormalities. Patients with abnormal liver function tests were also more likely to have an elevated sedimentation rate and a positive anti-ENA during the course of their disease.

ConclusionLiver involvement is a common complication in 1°SS. Its presence correlates with systemic disease. We consider that this complication should be routinely sought in patients with 1°SS, especially when a positive anti-ENA or evidence of systemic inflammation is found.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-230X-2-21 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Mariana J Kaplan - Robert W Ike


Documentos relacionados